Leukocytosis and MPNs: Where do we stand?

References

• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–1138.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35(5):702–711.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Nicolas C. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020;42:100711.  
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar
• Marcellino BK, Verstovsek S, Mascarenhas J. The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication. Clin Lymphoma Myeloma Leuk. 2020;20(7):415–421.
   PubMed Web of Science ®Google Scholar
• Ronner L, Podoltsev N, Gotlib J, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135(19):1696–1703.
   PubMed Web of Science ®Google Scholar
• Gangat N, Strand J, Li C-Y, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354–358.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(16):2732–2736.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Catani L, et al. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90(8):933–938.
   PubMed Web of Science ®Google Scholar
• Curto‐Garcia N, Ianotto JC, Harrison CN. What is pre‐fibrotic myelofibrosis and how should it be managed in 2018? Br J Haematol. 2018;183(1):23–34.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo clinic experience. Mayo Clin Proc. 2012;87(1):25–33.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. J Am Soc Hematol. 2000;96(13):4261–4266.
   Google Scholar
• Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87(4):269–276.
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. haematologica. 2006;91(2):169–175.
   PubMed Web of Science ®Google Scholar
• Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30 374 individuals. Eur Heart J. 2004;25(15):1287–1292.
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Jama. 1998;279(18):1477–1482.
   PubMed Web of Science ®Google Scholar
• Balta S, Celik T, Mikhailidis DP, et al. The relation between atherosclerosis and the neutrophil–lymphocyte ratio. Clin Appl Thromb Hemost. 2016;22(5):405–411.
   PubMed Web of Science ®Google Scholar
• Rudolph V, Steven D, Gehling UM, et al. Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease. Free Radic Biol Med. 2007;42(4):460–465.
   PubMed Web of Science ®Google Scholar
• Harlan JM, Killen PD, Harker LA, et al. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest. 1981;68(6):1394–1403.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. J Am Soc Hematol. 2008;112(10):4061–4068.
   Google Scholar
• Cashell AW, Buss DH. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states. Ann Hematol. 1992;64(6):273–276.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Drouin A, Massé JM, et al. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma. 2002;43(4):719–724.
   PubMed Web of Science ®Google Scholar
• Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood. 2004;104(12):3573–3580.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8(1):2–6.
   PubMedGoogle Scholar
• Haider M, Gangat N, Lasho T, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91(4):390–394.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia Blood. J Am Soc Hematol. 2008;112(8):3135–3137.
   Google Scholar
• Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood. 2007;109(9):4105.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270–276.
   PubMed Web of Science ®Google Scholar
• Girodon F, Dutrillaux F, Broséus J, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900–903.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low‐risk essential thrombocythemia and polycythemia vera. Blood. Cancer. 2009;115(24):5740–5745.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pascutto C, et al. Increase in leukocyte count over time predicts thrombosis in patients with low‐risk essential thrombocythemia. J Thromb Haemost. 2009;7(9):1587–1589.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97–100.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients Blood. J Am Soc Hematol. 2011;117(22):5857–5859.
   Google Scholar
• Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729–1737.
   PubMed Web of Science ®Google Scholar
• Ronner L, Mascarenhas J, Moshier EL. Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera. Blood Adv. 2019;3(20):3010–3012.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Gangat N, Coltro G, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11(4):1–4.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78(1):617–621.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–2452.
   PubMed Web of Science ®Google Scholar
• Gangat N, Strand J, Li CY, et al. The impact of leukocytosis on survival, leukemic transformation, and thrombosis in polycythemia vera. J Clin Oncol. 2007;25(18_suppl):7029–7029.
   Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574–1579.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.
   PubMed Web of Science ®Google Scholar
• Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560–561.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21(9):1952–1959.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55–60.
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors.Blood. J Am Soc Hematol. 2010;115(4):778–782.
   Google Scholar
• Elliott MA, Pardanani A, Lasho TL, et al. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788–1791.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood. J Am Soc Hematol. 2009;114(5):937–951.
   Google Scholar
• Buxhofer‐Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012;87(7):669–672.
   PubMed Web of Science ®Google Scholar
• Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017;96(10):1595–1604.
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Testoni N, et al. Long‐term follow‐up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84(4):215–220.
   PubMed Web of Science ®Google Scholar
• Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):e366.
   PubMedGoogle Scholar
• Abdulkarim K, Ridell B, Johansson P, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148–155.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–3184.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–761.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. haematologica. 2008;93(11):1645–1651.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. InMayo Clinic Proceedings. 2006;81(2):159–166.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21–30.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis Blood. J Am Soc Hematol. 2008;111(7):3383–3387.
   Google Scholar
• Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients. Br J Haematol. 2013;160(2):251–254.
   PubMed Web of Science ®Google Scholar
• Barraco D, Cerquozzi S, Hanson CA, et al. Cytogenetic findings in WHO‐defined polycythaemia vera and their prognostic relevance. Br J Haematol. 2018;182(3):437–440.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291–302.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis Blood. J Am Soc Hematol. 2017;129(24):3227–3236.
   Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment) blood. J Am Soc Hematol. 2010;115(9):1703–1708.
   Google Scholar
• Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083–2088.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients Blood., J Am Soc Hematol. 2010;115(22):4350–4355.
   Google Scholar
• Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–1018.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–2731.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. Blood. 2014;124(21):405–405.
   Web of Science ®Google Scholar
• Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. Am Soc Clin Oncol. 36(4):310–318.
   PubMed Web of Science ®Google Scholar
• Ferrer-Marín F, Cuenca-Zamora EJ, Guijarro-Carrillo PJ, et al. Emerging role of neutrophils in the thrombosis of chronic myeloproliferative neoplasms. Int J Mol Sci. 2021;22(3):1143.
   PubMed Web of Science ®Google Scholar
• Farrukh F, Guglielmelli P, Loscocco GG, et al. Deciphering the individual contribution of absolute neutrophil, lymphocyte and monocyte counts to thrombosis risk in patients with myeloproliferative neoplasms. Blood. 2021;138(Supplement 1):3651–3651.
   Google Scholar
• Carobbio A, Vannucchi AM, De Stefano V, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022;12(2):1–6.
   PubMed Web of Science ®Google Scholar